Abstract:4577 Background: Hepatocellular carcinoma (HCC) is a leading cause of cancer-related deaths worldwide. Though biannual ultrasound surveillance with or without alpha-fetoprotein (AFP) testing is recommended for at-risk patients, its sensitivity for early-stage HCC detection is suboptimal. We therefore evaluated performance of a biomarker panel incorporating methylated DNA markers (MDMs) and proteins for early HCC detection in at-risk patients with chronic liver disease. Methods: In an international, multicenter, case-control study, blood specimens were collected from patients with HCC per AASLD criteria and controls matched for age and liver disease etiology. All patients had underlying cirrhosis or chronic HBV infection. Whole blood was collected in cell-free DNA stabilizing and serum-separation tubes and shipped to a central laboratory for processing. The levels of 5 MDMs, AFP, and AFP-L3 were assessed along with age and sex. We used 537 samples in a 5-fold validation for developing a LASSO regression algorithm to classify samples as HCC positive or negative. Model robustness was tested by perturbing the data in silico and analyzing results with the predictive algorithm. Algorithm performance was compared to AFP alone and the GALAD score (Gender, Age, AFP-L3, AFP, and DCP). Results: The study included 136 HCC cases (81 early-stage—BCLC stage 0/A) and 401 controls. With specificity set at 89%, we developed a model using sex, AFP, and 3 MDMs (HOXA1, TSPYL5, B3GALT6) with higher sensitivity (70%) for early-stage HCC compared to GALAD (54%) or AFP (31% at 20 ng/mL or 52% at ≥7.7 ng/mL) (Table). The AUC for the HCC marker panel was 0.91 (95% CI 0.89 – 0.94) compared to GALAD (0.88; 95% CI 0.85 – 0.91) or AFP (0.84; 95% CI 0.81 – 0.87). The panel performed similarly in viral (AUC = 0.94) and non-viral (AUC = 0.89) etiologies. Conclusions: The robust algorithm based on novel blood-based biomarkers presented here provides higher sensitivity for early-stage HCC compared to other available blood-based biomarkers and, therefore, could significantly impact HCC clinical management and patient outcomes. Further clinical studies to validate the algorithm are ongoing. Clinical trial information: NCT03628651 . Performance of HCC marker panel. Sensitivity % (95% CI) Specificity % (95% CI) All-Stage AUC (95% CI) Early-Stage All-Stage Current HCC marker panel 70 (60 – 80) 81 (74 – 87) 89 (86 – 92) 0.91 (0.89 – 0.94) GALAD 54 (43 – 65) 68 (59 – 75) 89 (86 – 92) 0.88 (0.85 – 0.91) AFP (≥7.7 ng/mL) 52 (41 – 63) 64 (56 – 72) 89 (86 – 92) 0.84 (0.81 – 0.87) AFP (20 ng/mL) 31 (21 – 42) 46 (38 – 55) 98 (96 – 99)

A novel immunodiagnosis panel for hepatocellular carcinoma based on bioinformatics and the autoantibody‐antigen system

Combination of an autoantibody panel and alpha-fetoprotein for early detection of hepatitis B virus-associated hepatocellular carcinoma

Autoantibody signature in hepatocellular carcinoma using seromics

Autoantibodies to Tumor-Associated Antigens Combined with Abnormal Alpha-Fetoprotein Enhance Immunodiagnosis of Hepatocellular Carcinoma

Identification of hepatocellular-carcinoma-associated antigens and autoantibodies by serological proteome analysis combined with protein microarray.

Screening of Autoantibodies As Potential Biomarkers for Hepatocellular Carcinoma by Using T7 Phase Display System.

Antibody Detection Using Tumor-Associated Antigen Mini-Array in Immunodiagnosing Human Hepatocellular Carcinoma

Proteome Microarray Identifies Autoantibody Biomarkers for Diagnosis of Hepatitis B-related Hepatocellular Carcinoma.

Multimarker Panels for Detection of Early Stage Hepatocellular Carcinoma: A Prospective, Multicenter, Case‐Control Study

A Panel of Five Plasma Proteins for the Early Diagnosis of Hepatitis B Virus-Related Hepatocellular Carcinoma in Individuals at Risk

Applicability of the Multiplex Quantitative Antibody Array System for Early Diagnosis of Hepatocellular Carcinoma

Tumor-associated Autoantibodies Are Useful Biomarkers in Immunodiagnosis of Α-Fetoprotein-negative Hepatocellular Carcinoma

Algorithm for blood-based panel of methylated DNA and protein markers to detect early-stage hepatocellular carcinoma with high specificity.

Identification of Tumor-Associated Antigens in Human Hepatocellular Carcinoma by Autoantibodies.

A Novel Blood-Based Panel of Methylated DNA and Protein Markers for Detection of Early-Stage Hepatocellular Carcinoma

Autoantibodies to tumor-associated antigens as biomarkers in human hepatocellular carcinoma (HCC)

Discovering Panel of Autoantibodies for Early Detection of Lung Cancer Based on Focused Protein Array

Serum autoantibody measurement for the detection of hepatocellular carcinoma

Utility Of An Immunostaining Panel For Diagnosis Of Hepatocellular Carcinoma In Fine Needle-Aspiration Biopsies Of The Liver

Anti-BIRC5 Autoantibody Serves As a Valuable Biomarker for Diagnosing AFP-negative Hepatocellular Carcinoma

Serum Proteins, HMMR, NXPH4, PITX1 and THBS4; A Panel of Biomarkers for Early Diagnosis of Hepatocellular Carcinoma